Best Practice & Research Clinical Rheumatology
Volume 21, Issue 4 , Pages 687-697 , August 2007

Monitoring systemic lupus erythematosus in standard clinical care

  • Michelle Petri, MD, MPH (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +1 410 955 3823; Fax: +1 410 614 0498.

References 

  1. Barr S, Zonana-Nacach A, Magder L, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis and Rheumatism. 1999;42:2682–2688
  2. Ho A, Magder L, Barr S, Petri M. Decreases in anti-double stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis and Rheumatism. 2001;44:2342–2349
  3. Ho A, Magder LS, Barr SG, Petri MA. A decrease in complement is associated with increased renal and hematologic flares in patients with systemic lupus erythematosus. Arthritis and Rheumatism. 2001;44:2350–2357
  4. Gladman DD, Hirani N, Ibanez D, Urowitz MB. Clinically active serologically quiescent systemic lupus erythematosus. The Journal of Rheumatology. 2003;30(9):1960–1962
  5. Buyon JP, Clancy RM. Neonatal lupus: basic research and clinical perspectives. Rheumatic Diseases Clinics of North America. 2005;31(2):299–313vii
  6. Cnossen JS, de Ruyter-Hanhijarvi H, van der Post JA, et al. Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review. Acta Obstetricia et Gynecologica Scandinavica. 2006;85(5):519–525
  7. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis and Rheumatism. 2005;52(2):514–521
  8. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis and Rheumatism. 2006;54(2):421–432
  9. Middendorf DF, Hebert LA, Zager RA, et al. Simple method for monitoring 24-hour urinary urea nitrogen excretion. The Journal of Laboratory and Clinical Medicine. 1986;108(6):577–580
  10. Christopher-Stine L, Petri M, Astor BC, Fine D. Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. The Journal of Rheumatology. 2004;31(8):1557–1559
  11. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. The Journal of Rheumatology. 1992;19:53–59
  12. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. The New England Journal of Medicine. 2005;353:2550–2558
  13. Ibanez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. The Journal of Rheumatology. 2005;32(5):824–827
  14. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. The Quarterly Journal of Medicine. 1993;86(7):447–458
  15. Yee CS, Farewell V, Isenberg DA, et al. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis and Rheumatism. 2006;54(10):3300–3305
  16. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College Rheumatology damage index for sytemic lupus erythematosus. Arthritis and Rheumatism. 1996;39:363–369
  17. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis and Rheumatism. 2000;43:1801–1808
  18. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis and Rheumatism. 1996;39(11):1791–1801
  19. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. The New England Journal of Medicine. 2006;355(16):1647–1659
  20. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort:an update. Arthritis Care and Research. 1995;8:137–145
  21. Mont MA, Fairbank AC, Petri M, Hungerford DS. Core decompression for osteonecrosis of the femoral head in systemic lupus erythematosus. Clinical Orthopaedics. 1997;Jan:91–97
  22. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Journal of Clinical Oncology. 2005;23(34):8580–8587
  23. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Annals of Internal Medicine. 1992;117:997–1002
  24. Petri M, Roubenoff R, Dallal GE, et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996;348:1120–1124
  25. McMahon JA, Green TJ, Skeaff CM, et al. A controlled trial of homocysteine lowering and cognitive performance. The New England Journal of Medicine. 2006;354(26):2764–2772
  26. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA: The Journal of the American Medical Association. 2006;296(22):2720–2726
  27. McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology. 2005;64(2):297–303
  28. Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis and Rheumatism. 1999;42(4):728–734
  29. Menon S, Jameson-Shortall E, Newman SP, et al. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis and Rheumatism. 1999;42(4):735–741
  30. Leritz E, Brandt J, Minor M, et al. Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus. Journal of Clinical and Experimental Neuropsychology. 2002;24(4):527–533
  31. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288(5472):1765–1769
  32. Marmor MF. New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis and Rheumatism. 2003;48(6):1764
  33. Urowitz MB, Bookman AAM, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. The American Journal of Medicine. 1976;60:221–225
  34. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. American Journal of Epidemiology. 1997;145(5):408–415
  35. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis and Rheumatism. 2001;44(10):2331–2337
  36. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA: The Journal of the American Medical Association. 2003;289(19):2560–2572
  37. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Archives of Internal Medicine. 1988;148:36–39
  38. Shidham G, Hebert LA. Timed urine collections are not needed to measure urine protein excretion in clinical practice. American Journal of Kidney Diseases. 2006;47(1):8–14
  39. Hebert LA. Optimizing ACE-inhibitor therapy for chronic kidney disease. The New England Journal of Medicine. 2006;354(2):189–191
  40. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. The New England Journal of Medicine. 2006;354(23):2443–2451
  41. Boumpas DT, Austin HA, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Annals of Internal Medicine. 1993;119:366–369
  42. Somers EC, Marder W, Christman GM, et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis and Rheumatism. 2005;52(9):2761–2767
  43. Dooley MA, Patterson CC, Hogan SL, et al. Preservation of ovarian function using depot leuprolide acetate during cyclophosphamide therapy for severe lupus nephritis. Arthritis and Rheumatism. 2000;43:2858;[ abstract]
  44. Akkasilpa S, Goldman D, Magder LS, Petri M. Number of fibromyalgia tender points is associated with health status in patients with systemic lupus erythematosus. The Journal of Rheumatology. 2005;32(1):48–50
  45. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA: The Journal of the American Medical Association. 2004;292(19):2388–2395

PII: S1521-6942(07)00004-6

doi: 10.1016/j.berh.2007.01.003

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 4 , Pages 687-697 , August 2007

Article Tools

* Image Usage & Resolution